Alaunos Therapeutics Inc (TCRT)

$2.58 -0.09 (-3.26%)
Market Cap 6.41M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -41,800.00%
Debt to Equity Ratio 0.00
Volume 3,300
Avg Vol 15,660
Day's Range N/A - N/A
Shares Out 2.40M
Stochastic %K 40%
Beta -1.13
Analysts Strong Buy
Price Target $3.00

Company Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos T...

Industry: Biotechnology
Sector: Healthcare
Phone: 346 355 4099
Address:
2617 Bissonnet Street, Suite 233, Houston, United States
BillionerOfKing
BillionerOfKing May. 1 at 1:20 AM
$TCRT Current Stock Price: $2.55
0 · Reply
eman1200
eman1200 Apr. 30 at 4:39 PM
$TCRT has this been delisted or something?
0 · Reply
ritamargarita
ritamargarita Apr. 16 at 4:11 PM
$TCRT biotech setup, needs volume confirmation
0 · Reply
focafoca99
focafoca99 Apr. 15 at 9:13 PM
$TCRT disclosed a Nasdaq notice for failing the minimum stockholders' equity requirement and said it plans to submit a compliance plan.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 3:07 PM
$TCRT RSI: 49.32, MACD: -0.1003 Vol: 0.14, MA20: 2.66, MA50: 3.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 3:01 PM
$TCRT Holding firm at these levels. Buyers keep stepping in on dips. This shows real demand.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 11 at 11:48 AM
$TCRT Current Stock Price: $2.78
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 7:14 AM
$TCRT Great piece that accurately captures TCRT's current position. So if you want to refresh your understanding of TCRT or learn about TCRT for the first time, this is essential reading. https://everyticker.com/quote/TCRT/analysis/tcrt-s-existential-gamble-a-micro-cap-biotech-bets-its-remaining-cash-on-preclinical-obesity-nasdaq-tcrt
0 · Reply
PaulLaurent
PaulLaurent Jan. 13 at 6:36 AM
🚀📈 Top Gainers 📈🚀 AH $ZGM $JG $JYD $TVGN $TCRT
0 · Reply
CryptoKatt
CryptoKatt Jan. 2 at 11:22 AM
$TCRT What happened to Ziopharm and captain Kirk?
0 · Reply
Latest News on TCRT
Valion Bio Appoints Melinda Lackey as General Counsel

May 4, 2026, 4:05 PM EDT - 4 days ago

Valion Bio Appoints Melinda Lackey as General Counsel

VBIO

Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003

2026-03-02T11:43:28.000Z - 2 months ago

Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Mar 2, 2026, 6:30 AM EST - 2 months ago

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos Therapeutics files to sell 327,740 shares of common for holders

2025-10-22T10:40:47.000Z - 7 months ago

Alaunos Therapeutics files to sell 327,740 shares of common for holders

Alaunos Therapeutics files $50M mixed securities shelf

2025-08-21T10:10:16.000Z - 9 months ago

Alaunos Therapeutics files $50M mixed securities shelf

Alaunos prices 610,399 shares at $3.36 in registered direct offering

2025-06-23T17:00:26.000Z - 11 months ago

Alaunos prices 610,399 shares at $3.36 in registered direct offering

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics

2025-05-14T12:19:01.000Z - 1 year ago

PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics

ELAB

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025, 8:00 AM EDT - 1 year ago

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

ELAB

Alaunos Therapeutics reports Q3 EPS (4c) vs (4c) last year

2023-11-14T12:35:47.000Z - 2 years ago

Alaunos Therapeutics reports Q3 EPS (4c) vs (4c) last year

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Nov 14, 2023, 7:30 AM EST - 2 years ago

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Alaunos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2023-08-16T12:35:15.000Z - 2 years ago

Alaunos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw

2023-08-15T13:51:04.000Z - 2 years ago

Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw

Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)

2023-08-14T20:46:51.000Z - 2 years ago

Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

Jun 29, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 25, 2023, 5:00 PM EDT - 3 years ago

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics Earnings Call Transcript: Q1 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q1 2023

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

May 3, 2023, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Apr 26, 2023, 12:30 PM EDT - 3 years ago

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Precigen amends exclusive license agreement with Alaunos Therapeutics

2023-04-03T20:32:42.000Z - 3 years ago

Precigen amends exclusive license agreement with Alaunos Therapeutics

PGEN

Alaunos Therapeutics appoints Hofmeister to board of directors

2023-03-30T11:19:27.000Z - 3 years ago

Alaunos Therapeutics appoints Hofmeister to board of directors

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Mar 29, 2023, 5:30 PM EDT - 3 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Alaunos Therapeutics assumed with an Overweight at Wells Fargo

2023-03-27T12:38:03.000Z - 3 years ago

Alaunos Therapeutics assumed with an Overweight at Wells Fargo

Alaunos Therapeutics Earnings Call Transcript: Q4 2022

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q4 2022

Alaunos Therapeutics reports Q4 EPS (4c), consensus (7c)

2023-03-07T12:13:58.000Z - 3 years ago

Alaunos Therapeutics reports Q4 EPS (4c), consensus (7c)

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 7, 2023, 7:00 AM EST - 3 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Feb 28, 2023, 4:01 PM EST - 3 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Jan 9, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 29, 2022, 9:01 AM EST - 3 years ago

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

Nov 28, 2022, 4:01 PM EST - 3 years ago

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

Alaunos Therapeutics Earnings Call Transcript: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q3 2022

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Nov 14, 2022, 7:00 AM EST - 3 years ago

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Nov 8, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Nov 7, 2022, 8:00 AM EST - 3 years ago

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Sep 21, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Sep 7, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Aug 24, 2022, 3:00 PM EDT - 4 years ago

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics Earnings Call Transcript: Q2 2022

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Earnings Call Transcript: Q2 2022

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Aug 15, 2022, 7:00 AM EDT - 4 years ago

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 8, 2022, 8:50 AM EDT - 4 years ago

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Aug 4, 2022, 5:00 PM EDT - 4 years ago

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

CellChorus Announces Scientific Advisory Board

Jun 1, 2022, 11:39 AM EDT - 4 years ago

CellChorus Announces Scientific Advisory Board

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

May 26, 2022, 5:01 PM EDT - 4 years ago

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics Earnings Call Transcript: Q1 2022

May 16, 2022, 8:43 AM EDT - 4 years ago

Alaunos Therapeutics Earnings Call Transcript: Q1 2022

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 16, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 10, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 9, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022, 4:31 PM EDT - 4 years ago

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

May 2, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 30, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

Mar 16, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Mar 8, 2022, 4:05 PM EST - 4 years ago

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Jan 26, 2022, 7:00 AM EST - 4 years ago

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 9, 2021, 8:05 AM EST - 4 years ago

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 8, 2021, 4:10 PM EST - 4 years ago

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

Nov 1, 2021, 4:30 PM EDT - 4 years ago

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

Sep 27, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

Ziopharm Oncology to Participate in September Investor Conferences

Sep 1, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology to Participate in September Investor Conferences

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Aug 30, 2021, 8:30 AM EDT - 5 years ago

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

Jul 26, 2021, 4:30 PM EDT - 5 years ago

Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

Ziopharm Oncology to Participate in Upcoming Conferences

May 24, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology to Participate in Upcoming Conferences

Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting

May 19, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting

Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates

May 6, 2021, 4:02 PM EDT - 5 years ago

Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates

Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley '21 Two-Day Live Virtual Educational Symposium

May 4, 2021, 8:00 AM EDT - 5 years ago

Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley '21 Two-Day Live Virtual Educational Symposium

BillionerOfKing
BillionerOfKing May. 1 at 1:20 AM
$TCRT Current Stock Price: $2.55
0 · Reply
eman1200
eman1200 Apr. 30 at 4:39 PM
$TCRT has this been delisted or something?
0 · Reply
ritamargarita
ritamargarita Apr. 16 at 4:11 PM
$TCRT biotech setup, needs volume confirmation
0 · Reply
focafoca99
focafoca99 Apr. 15 at 9:13 PM
$TCRT disclosed a Nasdaq notice for failing the minimum stockholders' equity requirement and said it plans to submit a compliance plan.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 3:07 PM
$TCRT RSI: 49.32, MACD: -0.1003 Vol: 0.14, MA20: 2.66, MA50: 3.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 3:01 PM
$TCRT Holding firm at these levels. Buyers keep stepping in on dips. This shows real demand.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 11 at 11:48 AM
$TCRT Current Stock Price: $2.78
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 7:14 AM
$TCRT Great piece that accurately captures TCRT's current position. So if you want to refresh your understanding of TCRT or learn about TCRT for the first time, this is essential reading. https://everyticker.com/quote/TCRT/analysis/tcrt-s-existential-gamble-a-micro-cap-biotech-bets-its-remaining-cash-on-preclinical-obesity-nasdaq-tcrt
0 · Reply
PaulLaurent
PaulLaurent Jan. 13 at 6:36 AM
🚀📈 Top Gainers 📈🚀 AH $ZGM $JG $JYD $TVGN $TCRT
0 · Reply
CryptoKatt
CryptoKatt Jan. 2 at 11:22 AM
$TCRT What happened to Ziopharm and captain Kirk?
0 · Reply
CloudCharm
CloudCharm Dec. 27 at 2:16 PM
$TCRT Positioning reflects caution while awaiting confirmable progress; unit economics must show steady improvement — a credible cadence of milestones would shift sentiment. The thesis tightens only when delivery matches ambition.
0 · Reply
CryptoKatt
CryptoKatt Dec. 23 at 3:36 PM
$TCRT Rob Cos still pumping this pos?
0 · Reply
JimboSlice10
JimboSlice10 Dec. 10 at 8:31 PM
$TCRT next one to run big?
1 · Reply
legaleagle96
legaleagle96 Dec. 5 at 8:50 AM
$TCRT whats the catalyst here
1 · Reply
Estimize
Estimize Nov. 20 at 11:00 AM
$TCRT reported - EPS and - revenue for Q3. http://www.estimize.com/intro/tcrt?chart=historical&metric_name=eps&utm_content=TCRT&utm_medium=
0 · Reply
Frab
Frab Nov. 17 at 4:49 PM
$TCRT LFG
0 · Reply
isnarla
isnarla Nov. 11 at 2:59 PM
$TCRT finally moving
0 · Reply
LesleyMoore494
LesleyMoore494 Oct. 21 at 4:51 PM
$TCRT progressing in cancer therapy; AITX progressing in AI therapy for industries — clear proof of discipline and growth.
0 · Reply
shay7557
shay7557 Oct. 17 at 2:34 PM
$SGMO Sold the other half. Learned my lesson with $TCRT
1 · Reply
coldfacts
coldfacts Oct. 16 at 8:32 PM
$TCRT 👀
0 · Reply